No funding was specifically associated with the preparation of this manuscript.
This review examines recent randomized controlled cardiovascular (CV) outcome trials of glucose-lowering therapies in type 2 diabetes and their impact on the treatment of patients with type 2 diabetes. The trials were designed to comply with regulatory requirements to confirm that major adverse cardiac events (MACE) are not detrimentally affected by such therapies. Trials involving dipeptidyl peptidase-4 (DPP-4) inhibitors did not alter a composite MACE outcome comprising CV deaths, non-fatal myocardial infarction and non-fatal stroke; however, the possibility that some members of this class might incur a small increased risk or worsening of heart failure cannot be excluded. Some studies on glucagon-like peptide-1 receptor agonists (liraglutide: LEADER trial; semaglutide: SUSTAIN-6 trial) found significant benefits for MACE, while treatment with sodium-glucose co-transporter-2 inhibitors (empagliflozin: EMPA-REG OUT-COME trial; canagliflozin: CANVAS trial) also significantly reduced MACE and reduced hospitalization for heart failure. Comparisons among trials are complicated by variance in the populations recruited, particularly CV status at randomization, and differences in trial design, data collection and analyses. A large proportion of patients recruited into these trials have previously experienced adverse CV events; thus, the therapies are mostly assessing secondary prevention of a further event. This contrasts with the overall type 2 diabetes population receiving glucose-lowering therapies, of whom the majority will not have had MACE and will be regarded as primary prevention. Overall, the trials provide reassuring evidence that new glucose-lowering medications do not adversely affect CV events and some of these agents may offer CV protection.
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| INTRODUCTION
Type 2 diabetes is a condition associated with high microvascular and macrovascular risk. [1] [2] [3] Management of chronic hyperglycaemia is essential to defer the onset and reduce the severity of microvascular complications, while early intervention to improve glycaemic control may also reduce long-term macrovascular risk. [4] [5] [6] Metformin, which is typically the preferred first-line pharmacological therapy to manage hyperglycaemia of type 2 diabetes, has been associated with reduced cardiovascular (CV) risk, and several other glucose-lowering therapies have recently been reported to offer CV benefits. 7, 8 The CV effects of these glucose-lowering agents appear to be largely independent of their glucose-lowering efficacy, although they may involve mechanisms linked to glucose-lowering.
In the present review, we assess the current evidence regarding the CV effects of newer glucose-lowering agents and the importance of this evidence for the management of metabolic control and CV risk in type 2 diabetes.
| GLYCAEMIC CONTROL AND CV RISK
Although improved medical and interventional therapies have markedly reduced CV risk in patients with type 2 diabetes in recent decades, the risk of premature CV death, myocardial infarction (MI), stroke, heart failure and related adverse CV events is approximately doubled in people with type 2 diabetes compared to those without. 1, 3 Whereas good glycaemic control reduces the long-term burden of microvascular complications, such as retinopathy and kidney disease, it is unclear whether good glycaemic control itself reduces CV disease in type 2 diabetes. 4, 5 An increasing amount of evidence suggests a deferred benefit of early intensive glycaemic control in reducing the risk of adverse CV events many years or decades later, 5 but, when glycaemic management is started or intensified late in the natural course of type 2 diabetes, the impact on macrovascular disease appears to be limited. 4, 9 Indeed, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, highly intensive glycaemic control in long established and poorly contolled type 2 diabetes was associated with 22% excess CV mortality, prompting early termination of the intensive arm of the trial 9 ; however, further analysis of the intensively treated group showed that the high mortality within that group was attributable mostly to individuals who actually exhibited poor glycaemic control.
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Until 2008, the approval of new agents to treat diabetes focused almost exclusively on glucose-lowering efficacy. Since that time, the regulatory landscape has changed considerably, and new agents must demonstrate CV safety (to designated margins for the US Food and Drug Administration [FDA] ) to achieve or maintain regulatory approval. 11, 12 This has led to a rapid proliferation of clinical trials to assess CV outcomes for the new agents and some older glucoselowering therapies (Table 1) . 4 | ANTIDIABETIC DRUGS AND CV EFFECTS
| Metformin
The rationale for the use of metformin as first-line glucose-lowering pharmacological therapy in type 2 diabetes reflects its glucose-lowering efficacy while avoiding significant hypoglycaemia or weight gain 8, 21 ; however, metformin counters insulin resistance, lowers basal hyperinsulinaemia and has been associated with reduced long-term CV risk in prospective controlled trials, observational studies and database analyses (reviewed in Bailey 22 ). In the United Kingdom Prospective Diabetes Study (UKPDS), metformin treatment of 342 newly diagnosed overweight people with type 2 diabetes reduced MI by 39%, coronary deaths by 50%, stroke by 41% and all-cause mortality by 36% after a median of 10.7 years compared with non-pharmacological treatment. 23 These reductions in major CV events were greater than with intensive therapy using a sulphonylurea or insulin. Follow-up for a further 8 to 10 years when all patients received intensive therapy found that the reduced risk of MI and mortality with initial metformin therapy persisted compared with early treatment using a sulphonylurea or insulin. 4 It is emphasized that the CV benefits of metformin become evident after a period of several years; thus, as illustrated in a meta-analysis of randomized trials with metformin, improved CV outcomes are seldom evident in short-term studies. 24 Observational and database studies also provide consistent evidence of a long-term reduction in CV risk and increased survival for people with type 2 diabetes receiving metformin compared with dietonly, sulphonylureas, acarbose and insulin. 25 Indeed, patients treated with metformin to achieve glycated haemoglobin (HbA1c) <48 mmol/ mol (<6.5%) in their first 6 months of treatment had a lower mortality rate over the following 10 years compared with individuals who did not achieve such early control. 26 This affirms the value of effective early use of metformin to defer CV events years later. Regarding the mechanisms, considerable evidence has linked the improved CV prognosis of metformin-treated people with type 2 diabetes to a reduction in insulin resistance and improvements in endothelial function and thrombolysis. 22 Metformin can assist lipid-lowering in patients with overt hyperlipidaemia, but this does not appear to be sufficient to explain the protracted CV benefits in type 2 diabetes. Most of these trials were designed to fulfil US Food and Drug Administration (FDA) criteria to confirm cardiovascular (CV) safety versus placebo (placebo includes standard of care with other glucose-lowering agents). CAROLINA, DEVOTE and TOSCA.IT were designed to compare CV safety between two agents. The primary endpoint for most studies was a composite three-point MACE (CV death, non-fatal myocardial infarction, non-fatal stroke), although some trials (TECOS and ELIXA) were intiated in advance of the 2008 guidance from the FDA and use a primary composite four-point MACE (the threepoint MACE plus hospitalization for unstable angina). a ACE was conducted in people with IGT.
15%). 4, 29 In an analysis of 115 randomized trials in people with type 2 diabetes, sulphonylurea therapy increased mortality by 22% compared with placebo or other glucose-lowering therapies, but the overall incidence of MACE was unaffected. 30 Two further recent analyses have concluded that sulphonylurea therapy increases the risk of CV deaths compared with other oral glucose-lowering therapies: CV deaths were increased by 27% in an analysis of 33 studies, and by 46% in an analysis of 82 randomized controlled trials 31, 32 ;
however, another recent analysis of 47 randomized trials in people with type 2 diabetes found no increase in CV mortality with use of a sulphonylurea, including add-on to metformin. 33 Sulphonylurea therapy in overweight patients in the UKPDS was less beneficial than metformin, 23 and an evaluation of 14 randomized trials comparing the two agents suggested that sulphonylurea therapy carries a 47%
greater risk of CV mortality than metformin, although this was not quite statistically significant. 29 Thus, after >50 years, the differences among individual studies and among meta-analyses continue to cloud any firm conclusion, although the balance of evidence suggests that sulphonylurea therapy may be associated with a greater risk of fatal CV events than other oral glucose-lowering agents -mostly comparisons with metformin. An ongoing study is comparing CV outcomes of patients with type 2 diabetes treated with linaglitpin versus glimepiride (CAROLINA study: CARdiovascular Outcome Trial of LINAgliptin). 34 Meglitinides, like sulphonylureas, lower blood glucose mainly by stimulating insulin secretion, but they act more rapidly and for a shorter duration than sulphonylureas. In the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, nateglinide did not alter CV outcomes in people with impaired glucose tolerance who were at high CV risk. and reduced risk of developing type 2 diabetes by 36% in people with impaired glucose tolerance. 36 This is consistent with evidence that a reduction in postprandial glucose excusions reduces CV risk 37 and may refect an effect of acarbose to increase glucagon-like peptide-1 (GLP-1) secretion. 38 However, the recently completed 5-year doubleblinded placebo-controlled Acarbose Cardiovascular Evaluation (ACE) trial in 6522 Chinese patients with coronary heart disease and impaired glucose tolerance found no effect of acarbose on a five-point composite MACE outcome of CV death, non-fatal MI, non-fatal stroke, hospital admission for unstable angina, and hospitalization for heart failure. 39 
| Thiazolidinediones
Thiazolidinediones are peroxisome proliferator-activated receptorgamma (PPARγ) agonists which lower blood glucose, at least in part, 
| CV OUTCOME TRIALS WITH RECENTLY AVAILABLE GLUCOSE-LOWERING DRUGS
The main prospective post-marketing CV outcome trials with glucoselowering agents (completed and on-going) designed to fulfil FDA criteria are listed in Table 1 . Those trials which have now completed and for which a detailed account of the outcome data has been published are shown in Table 2 . The primary endpoint is time to a three-point MACE (CV death, non-fatal MI, non-fatal stroke), although some trials (Table 3) . Moreover, the majority of patients with diabetes in usual clinical practice will be treated with glucose-lowering medication prior to a CV event (i.e. primary prevention), whereas the trial populations were selected to include a high proportion of patients who have already had an adverse CV event (i.e. secondary prevention). Small differences in trial design, duration, event prespecification, adjudication and analytical procedures, including interim analyses, add to the variance among between trials. Also, the extent to which statistical chance could contribute to perceived differences cannot be ignored.
For example, with regard to the statistical analyses, the 95% upper CI for the three-point MACE was 0.99 for empagliflozin, prespecified to be significant, whereas the value for exenatide was 1.00, narrowly missing statistical significance. Such marginal numerical differences can make huge differences to the reporting and interpretation of information across the medical media.
Various meta-analyses that include data from phase II/III studies have also assessed the CV effects of newer antidiabetic agents, but the current overview is focused on the large prospective controlled CV outcome trials as these provide the highest level of evidence. gested that patients with a high baseline N-terminal pro b-type natriuretic peptide (NT-proBNP), pre-existing heart failure or chronic kidney disease were more at risk of hospitalization for heart failure, and, in retrospect, it was evident that each of these risk factors was either more common or more severe amongst those randomized to saxagliptin. bradykinin and vasostatin. 63 These peptides can be degraded by peptidases other than DPP-4, and DPP-4 inhibitors have not been shown to adversely affect their physiological activity. Moreover, DPP-4 inhibitors may slightly improve the blood lipid profile and slightly lower blood pressure, 63, 64 and exert other potentially cardioprotective effects.
| Dipeptidyl peptidase-4 inhibitors
65,66
| GLP-1 receptor agonists
In addition to their glucose-lowering and weight-lowering actions, notably potentiating glucose-induced insulin secretion, reducing glucagon, delaying gastric emptying and inducing satiety, GLP-1 receptor agonists (GLP-1RAs) exert various effects on the CV system. For example, in people with type 2 diabetes, GLP-1RAs typically reduce blood pressure by 2 to 4 mm Hg, although they increase heart rate by 2 to 4 bpm, reduce inflammation and plasminogen activator inhibitor-1 and may improve the lipid profile. 67, 68 They also increase endothelial nitric oxide production and enhance vasorelaxation, reduce carotid intima-media thickness and improve the ejection fraction in people with type 2 diabetes with heart failure. 69 Studies in animals and isolated tissues indicate that GLP-1RAs exert cardioprotective effects against oxidative stress, enhance ventricular contractility, stabilize atheromatous plaque and improve the viability of cardiomyocytes. 70, 71 Evidence regarding the effects of GLP-1RAs on CV outcomes has been mostly favourable 72 : two of the four CV outcome studies showed a significant reduction in a three-point MACE (liraglutide in LEADER and semaglutide in SUSTAIN-6), and two reported no significant change (exenatide in EXSCEL and lixisenatide in ELIXA; Table 2 ). [73] [74] [75] [76] The LEADER trial randomized 9340 patients with type 2 diabetes who were at high CV risk to placebo or liraglutide 0.6 to 1.8 mg/d for 3.1 years. The three-point MACE was reduced by 13% in the liraglutide group, with a 22% reduction in CV death and a 15% reduction in total mortality. There was also a non-significant numerical reduction in non-fatal MI and non-fatal stroke. 74 The Kaplan-Meier curves for the three-point MACE showed a separation of events between liraglutide-and placebo-treated patients after 12 to 18 months, suggesting that the beneficial effect of liraglutide is not immediate and may be mediated by a reduction in atherosclerosisrelated events.
SUSTAIN-6 was actually a phase III pre-approval study with a much smaller population than LEADER, but the study design and patient population were similar to LEADER. SUSTAIN-6 randomized 3297 patients with type 2 diabetes and high CV risk to semaglutide 0.5 to 1.0 mg once weekly or placebo, and assessed CV outcomes after 2.1 years. 75 Semaglutide significantly reduced the three-point MACE by 26%, an effect that was mainly driven by a 39% reduction of non-fatal stroke. The EXSCEL trial randomized 14 752 patients with type 2 diabetes at high CV risk to once-weekly exenatide or placebo and, after 3.3 years, exenatide showed a numerical but nonsignificant reduction of the three-point MACE (HR 0.91, 95% CI 0.83-1.00; P = 0.061). In an intention-to-treat analysis there was a significant reduction in all-cause mortality by 14% (P = 0.016), which was considered exploratory because the primary endpoint did not show superiority. 76 To date, it remains unclear why liraglutide and semaglutide led to a significant reduction in the three-point MACE while lixisenatide and exenatide did not achieve a significant effect. oral semaglutide (PIONEER-6) and albiglutide (HARMONY).
| Sodium-glucose co-transporter-2 inhibitors
Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce renal glucose reabsorption, lowering blood glucose through glucosuria. Postmarketing CV outcome studies with the SGLT2 inhibitors empagliflozin (EMPA-REG OUTCOME) and canagliflozin (CANVAS programme)
found these agents to be associated with significant improvements in the three-point MACE. 79, 80 EMPA-REG OUTCOME randomized 7020 patients with type 2 diabetes and CV disease to empagliflozin 10 or 25 mg/d or placebo and patients were followed for 3.1 years. 79 Treatment of the CV risk of patients in EMPA-REG OUTCOME included >75% of patients receiving a statin, >95% receiving antihypertensive therapy and~90% of patients receiving anticoagulant/antiplatelet drugs. Mean blood pressure was 135/77 mm Hg and mean LDL cholesterol was 2.2 mmol/L. The study showed a significant 14% reduction of the three-point MACE, a 38% significant reduction of CV mortality, and a 32% significant reduction of overall mortality, translating into a number-needed-to-treat of 39 over 3.1 years to prevent one death. In addition, empagliflozin significantly reduced hospitalization for heart failure but did not alter the occurrence of non-fatal MI and stroke. 81 A notable feature of the EMPA-REG OUTCOME trial was the rapid divergence of the rate of the MACE, mortality and heart failure hospitalization between the empagliflozin and placebo groups within the first 6 months after randomization.
The CANVAS programme integrated data from two trials (CANVAS and CANVAS-R) and randomized 10 142 patients with type 2 diabetes at high CV risk to placebo or canagliflozin 100 to 300 mg/ d. 80 After 3.1 years, canagliflozin significantly reduced the three-point MACE by 14% but, in contrast to empagliflozin, did not significantly alter the occurrence of CV death or overall mortality. However, similar to the findings with EMPA-REG OUTCOME, canaglifozin significantly reduced hospitalization for heart failure. Notably, canagliflozin was associated with an increased incidence of fractures and amputations, as yet unexplained. Unlike the rapid divergence of the MACE between the empagliflozin and placebo groups in EMPA-REG OUTCOME, divergence of the MACE between the canagliflozin and placebo groups in CANVAS was more gradual. All patients randomized in the EMPA-REG OUTCOME trial had prior CV disease (hence essentially secondary prevention), but only 65% of patients at entry into CAN-VAS had prior CV disease (hence a mix of primary and secondary prevention). This may be relevant to the difference in time-to-effect between these trials and the marked reduction in CV deaths in EMPA-REG OUTCOME compared with the 'healthier' population recruited into CANVAS.
The CV benefits attributable to SGLT2 inhibitors could involve several mechanisms, partly related to the glucose-lowering mechanism, but mostly unrelated to the extent of glucose-lowering. [82] [83] [84] The glucosuric effect of SGLT2 inhibitors is independent of insulin, but the reduction in glucotoxicity has been shown to reduce insulin resistance and improve β-cell responsiveness, the former effect being a potential contributor to reduced CV risk. 85 The weight reduction associated with the glucosuric effect of SGLT2 inhibitor therapy is another potentially beneficial effect, but the CV advantages were evident too quickly to be attributable to decreased weight, reduced insulin resistance or reduced atherosclerosis. The osmotic diuresis that accompanies the glucosuria could contribute to haemodynamic benefits through reduced blood pressure and decreased intravascular volume during SGLT2 inhibitor therapy, and these effects are likely to improve CV outcomes similarly to conventional diuretic therapy. 86 The reduced hyperglycaemia favours utilization of fatty acids which, if coupled with reduced insulin, can increase ketone production, and it has been proposed that increased availability of ketones to the myocardium may contribute to improved cardiac energy metabolism. 87 Additionally, there is emerging evidence that the detrimental effect on the myocardiium of decreased catabolism of branched-chain amino acids in heart failure may be partially reversed by empagliflozin, providing a further mechanism through which SGLT2 inhibitors might improve myocardial energy metabolism. 88, 89 Another effect of SGLT2 inhibitors on the myocardium involves an inhibition of the sarcolemmal Na + /H + exchanger, which would lower intracellular sodium.
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SGLT2 inhibition can produce a small increase in glucagon, which might exert an inotropic effect and assist appetite control. 91 SGLT2
inhibitors can also inhibit renal urate reuptake and lower blood uric acid, which offers further potential vascular benefits. 92 A renoprotective effect of SGLT2 inhibition has been indicated by empagliflozin and canagliflozin being associated with significant reductions in the onset/progression of nephropathy (HR 0.61, 95% CI 0.53-0.70, and HR 0.73, 95% CI 0.67-0.79, respectively). 80, 93 This may be attributable to SGLT2 inhibition in the proximal tubules causing the delivery of more sodium to the macular densa which will increase adenosine release and adjust tubular-glomerular feedback to constrict afferent glomerular vessels. This will reduce glomerular pressure, reduce filtration and protect the glomerular capillaries. 94, 95 Ongoing CV outcome trials with SGLT2 inhibitors are DECLARE with dapagliflozin, VERTIS with ertugliflozin, and SCORED with sotagliflozin, the latter being an inhibitor of SGLT2 and SGLT1. population receiving glucose-lowering therapies, the majority of whom will not have had a MACE and will be regarded as primary prevention. 96 Heart failure is probably the most common cardiac condition in type 2 diabetes, and although it was not part of the primary composite of the MACE endpoint of these trials, the occurrence of hospitalization for heart failure was monitored and found to be much reduced with the SGLT2 inhibitors, irrespective of whether or not patients had a history of heart failure at randomization. 97, 98 However, given the diversity of instructions to patients, the proximity of hospitals, local procedures for hospital admission and likely variance in the risk and nature of the heart failure before and during the trials it is again difficult to compare among trials and may not be consistent within trials.
Beyond CV events, the CV outcome trials have provided valuable evidence regarding other safety concerns such as pancreatitis and neoplasms. The trials have also revealed potential benefits against diabetic kidney disease, with members of each of the three classes of agents examined (not considered in any detail herein), and suggested some aspects that deserve further study such as retinopathy progression with rapid glucose-lowering as well as peripheral vascular disease with glucosuria. While the CV outcome trials have focused attention on the association of macrovascular events with glucose-lowering agents, we should not be distracted from the importance of glucoselowering on microvascular disease because microvascular disturbances impact the severity of some macrovascular events, particularly within the myocardium, and account for much of the burden of advanced type 2 diabetes in kidney, eye and neuropathic complications.
Although CV outcome trials have been conducted with the more recently available classes of glucose-lowering agents, much evidence generated during 60 years of experience with metformin supports the long-term CV benefits associated with this agent, and there are many short-term studies to demonstrate a multitude of mechanisms through which metformin can benefit vascular health. The CV effects of sulphonylureas remain controversial, and 60 years of experience have yet to produce equivocal evidence, although an increased risk of hypoglycaemia remains a CV concern because episodes of neuroglycopenia can generate pronounced sympathetic responses and arrhythmias. Postprandial glycaemic excursions represent a CV risk, and the use of acarbose to reduce these excursions provided preliminary evidence of benefit in the Stop-NIDDM study, but a five-point MACE was not reduced by acarbose in the ACE study in a Chinese population. Although pioglitazone increases the risk of heart failure it has been shown to reduce the risk of three-point MACE in earlier studies, but the TOSCA.IT study found a similar occurrence of MACE when pioglitazone was compared with sulphonylurea therapy.
In summary, recent CV outcome trials have provided reassuring evidence that newer glucose-lowering agents used to manage hyperglycaemia in type 2 diabetes do not adversely affect the risk of CV death, non-fatal MI or stroke, and some may offer cardioprotective benefits.
